Lucentis vs PDT: which is more cost-effective?

February 11, 2009

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration, from the December 2008 issue of Clinical Therapeutics.

Please click here to read the abstract.